145 related articles for article (PubMed ID: 16184309)
1. Biophysical and pharmacological aspects of K+ channels in T lymphocytes.
Panyi G
Eur Biophys J; 2005 Aug; 34(6):515-29. PubMed ID: 16184309
[TBL] [Abstract][Full Text] [Related]
2. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
[TBL] [Abstract][Full Text] [Related]
3. Novel alpha-KTx peptides from the venom of the scorpion Centruroides elegans selectively blockade Kv1.3 over IKCa1 K+ channels of T cells.
Olamendi-Portugal T; Somodi S; Fernández JA; Zamudio FZ; Becerril B; Varga Z; Panyi G; Gáspár R; Possani LD
Toxicon; 2005 Sep; 46(4):418-29. PubMed ID: 16026809
[TBL] [Abstract][Full Text] [Related]
4. Potassium channels as therapeutic targets for autoimmune disorders.
Wulff H; Beeton C; Chandy KG
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
[TBL] [Abstract][Full Text] [Related]
5. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
6. Ion channels and lymphocyte activation.
Panyi G; Varga Z; Gáspár R
Immunol Lett; 2004 Mar; 92(1-2):55-66. PubMed ID: 15081528
[TBL] [Abstract][Full Text] [Related]
7. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity.
Baell JB; Gable RW; Harvey AJ; Toovey N; Herzog T; Hänsel W; Wulff H
J Med Chem; 2004 Apr; 47(9):2326-36. PubMed ID: 15084131
[TBL] [Abstract][Full Text] [Related]
8. Potassium channels in T lymphocytes: therapeutic targets for autoimmune disorders?
Vianna-Jorge R; Suarez-Kurtz G
BioDrugs; 2004; 18(5):329-41. PubMed ID: 15377175
[TBL] [Abstract][Full Text] [Related]
9. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels.
Koo GC; Blake JT; Shah K; Staruch MJ; Dumont F; Wunderler D; Sanchez M; McManus OB; Sirotina-Meisher A; Fischer P; Boltz RC; Goetz MA; Baker R; Bao J; Kayser F; Rupprecht KM; Parsons WH; Tong XC; Ita IE; Pivnichny J; Vincent S; Cunningham P; Hora D; Feeney W; Kaczorowski G
Cell Immunol; 1999 Nov; 197(2):99-107. PubMed ID: 10607427
[TBL] [Abstract][Full Text] [Related]
10. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
Wulff H; Calabresi PA; Allie R; Yun S; Pennington M; Beeton C; Chandy KG
J Clin Invest; 2003 Jun; 111(11):1703-13. PubMed ID: 12782673
[TBL] [Abstract][Full Text] [Related]
11. Novel alpha-KTx sites in the BK channel and comparative sequence analysis reveal distinguishing features of the BK and KV channel outer pore.
Giangiacomo KM; Becker J; Garsky C; Schmalhofer W; Garcia ML; Mullmann TJ
Cell Biochem Biophys; 2008; 52(1):47-58. PubMed ID: 18815746
[TBL] [Abstract][Full Text] [Related]
12. Potent Kv1.3 inhibitors from correolide-modification of the C18 position.
Bao J; Miao S; Kayser F; Kotliar AJ; Baker RK; Doss GA; Felix JP; Bugianesi RM; Slaughter RS; Kaczorowski GJ; Garcia ML; Ha SN; Castonguay L; Koo GC; Shah K; Springer MS; Staruch MJ; Parsons WH; Rupprecht KM
Bioorg Med Chem Lett; 2005 Jan; 15(2):447-51. PubMed ID: 15603971
[TBL] [Abstract][Full Text] [Related]
13. Ion channels in T cells: from molecular pharmacology to therapy.
Krasznai Z
Arch Immunol Ther Exp (Warsz); 2005; 53(2):127-35. PubMed ID: 15928581
[TBL] [Abstract][Full Text] [Related]
14. T-lymphocyte calcium influx characteristics and their modulation by Kv1.3 and IKCa1 channel inhibitors in the neonate.
Toldi G; Treszl A; Pongor V; Gyarmati B; Tulassay T; Vásárhelyi B
Int Immunol; 2010 Sep; 22(9):769-74. PubMed ID: 20601376
[TBL] [Abstract][Full Text] [Related]
15. Potassium channel expression in human CD4+ regulatory and naïve T cells from healthy subjects and multiple sclerosis patients.
Varga Z; Csepany T; Papp F; Fabian A; Gogolak P; Toth A; Panyi G
Immunol Lett; 2009 Jun; 124(2):95-101. PubMed ID: 19409928
[TBL] [Abstract][Full Text] [Related]
16. Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse.
Tóth A; Szilágyi O; Krasznai Z; Panyi G; Hajdú P
Immunol Lett; 2009 Jun; 125(1):15-21. PubMed ID: 19477198
[TBL] [Abstract][Full Text] [Related]
17. Increasing the molecular contacts between maurotoxin and Kv1.2 channel augments ligand affinity.
M'Barek S; Chagot B; Andreotti N; Visan V; Mansuelle P; Grissmer S; Marrakchi M; El Ayeb M; Sampieri F; Darbon H; Fajloun Z; De Waard M; Sabatier JM
Proteins; 2005 Aug; 60(3):401-11. PubMed ID: 15971207
[TBL] [Abstract][Full Text] [Related]
18. Ion channels in T lymphocytes: an update on facts, mechanisms and therapeutic targeting in autoimmune diseases.
Varga Z; Hajdu P; Panyi G
Immunol Lett; 2010 May; 130(1-2):19-25. PubMed ID: 20026117
[TBL] [Abstract][Full Text] [Related]
19. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Rangaraju S; Chi V; Pennington MW; Chandy KG
Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
[TBL] [Abstract][Full Text] [Related]
20. Kv1.3/Kv1.5 heteromeric channels compromise pharmacological responses in macrophages.
Villalonga N; Escalada A; Vicente R; Sánchez-Tilló E; Celada A; Solsona C; Felipe A
Biochem Biophys Res Commun; 2007 Jan; 352(4):913-8. PubMed ID: 17157812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
